What the study is
Hai-Chi Lv, Yu-Feng Fan and Xue-Jun Ge, at Shanxi Medical University School and Hospital of Stomatology in Taiyuan, published “Carnitine palmitoyltransferase 1A facilitates the senescence of human dental pulp stem cells by Parkin succinylation-mediated mitophagy” in the World Journal of Stem Cells as an article in press on 18 September 2026 (doi:10.4252/wjsc.122036; open access, CC BY-NC). The work uses a commercial Lonza human dental pulp stem cell (DPSC) line, comparing passage 7 cells against passage 15 cells as an in vitro model of replicative senescence. The starting observation is that CPT1A, best known as the rate-limiting enzyme of mitochondrial fatty-acid beta-oxidation, has a reported second catalytic identity as a lysine succinyltransferase (Kurmi et al., Cell Reports 2018), and that its role in cellular aging is unsettled: CPT1A loss promotes senescence in vascular endothelial cells but suppresses it in oxidatively stressed chondrocytes, so the direction in pulp stem cells was an open question.
What the experiments show
CPT1A mRNA and protein run higher in p15 than p7 DPSCs. Silencing CPT1A in p15 cells reduced the fraction of senescence-associated beta-galactosidase positive cells and lowered the senescence markers p53, p21, and p16, while restoring mitophagy by every readout the authors used: more mitochondria captured inside autophagosomes on transmission electron microscopy, higher PINK1, Parkin, and LC3B-II/I protein by immunoblot, and tighter lysosome-mitochondria colocalization. Forced CPT1A expression in young p7 cells produced the mirror image, reported in the supplementary data. Two epistasis experiments place mitophagy downstream of CPT1A: the mitophagy inhibitor Mdivi-1 and knockdown of Parkin each abolished the anti-senescence effect of CPT1A silencing.
The modification at the center
The novel claim is a post-translational one. Co-immunoprecipitation showed CPT1A and Parkin in complex; CPT1A knockdown cut Parkin succinylation without touching PINK1 succinylation. A GPSuc database prediction pointed to lysine 27, and a K27R point mutant bore that out: less succinylation, more Parkin protein, and a cycloheximide chase showed that CPT1A knockdown slows Parkin’s turnover. The cleanest experiment separates the two catalytic identities of the enzyme. A G710E mutant that disables the fatty-acid oxidation (CPTase) activity but leaves the succinyltransferase (LSTase) activity intact behaved like wild type, while H473A, which disables both, failed to restore Parkin succinylation or the suppression of mitophagy. The aging signal therefore rides on the succinyltransferase chemistry, not on fat burning. The authors state this is the first report of succinylation on Parkin at all; that is their priority claim, not an established fact of the literature.
The mouse arm, and its honest limits
For the in vivo half, eight-week-old male C57BL/6 mice received 150 mg/kg D-galactose by subcutaneous injection daily for six weeks, with tail-vein lentiviral sh-CPT1A or control given weekly; six mice per group. D-galactose raised CPT1A and Parkin succinylation in dental pulp, pushed p53, p21, and p16 up and PINK1, Parkin, and LC3B-II/I down, and produced disordered, loosely arranged pulp with immune-cell infiltration on H&E. CPT1A knockdown reversed each of these. The authors’ own limitations paragraph does part of the bounding for us: tail-vein lentivirus is systemic, so the pulp effect cannot be pinned on DPSCs alone; the K27 assignment rests on site-directed mutagenesis and awaits mass spectrometry; Mdivi-1 mainly blocks Drp1-driven fission and has off-target actions; and the K27R mutant was never tested for Parkin’s mitochondrial translocation or ubiquitin ligase activity. D-galactose is also a generalized aging model, not a pulp injury or repair model, and no functional pulp outcome was measured.
Boundary and what it changes
This is one commercial cell line, one replicative-senescence paradigm in dishes, and one systemic aging model in mice. It shows that a metabolic enzyme moonlighting as a succinyltransferase can set the senescence state of pulp stem cells by tagging a mitophagy driver, not that manipulating CPT1A improves pulp regeneration in any animal or person. Context-dependence cuts both ways: because CPT1A’s senescence role flips sign between cell types in prior work, the pro-senescent direction here should be read as pulp-specific until replicated. One peer-review flag from reading the full text: the reference list miscites at least one paper (a population-genetics study of cold-tolerance SNPs appears as support for CPT1A’s canonical enzymatic role), a small but real sign of editorial care. For the pulp-dentin repair program, the piece adds a concrete, druggable axis to the fast-growing senescence-mechanism literature the field has produced this year: if senescent DPSCs are a repair bottleneck, CPT1A-Parkin succinylation is a named place to intervene. The field assessment does not change on this record; it strengthens one mechanism inside one route and ranks behind the route’s animal and clinical evidence.
Provenance: grounded in the full text of Lv, Fan and Ge (2026), World Journal of Stem Cells, article in press 18 September 2026, doi:10.4252/wjsc.122036, retrieved as the publisher’s PDF on 22 September 2026. See /method/.